VIVUS, Inc. (NASDAQ:VVUS), a pharmaceutical company dedicated to the
development and commercialization of novel therapeutic products, today
announced that it will report financial results for the quarter ended
March 31, 2008, after the NASDAQ Market closes on Thursday May 8, 2008.
The company will conduct a conference call and an audio webcast at 1:30
p.m. PT on the same day.
Conference Call Information
Domestic callers: 1-888-873-4896
International callers: 1-617-213-8850
Passcode: 49923002
Webcast information: http://ir.vivus.com/
The webcast is also being distributed through the Thomson StreetEvents
Network to both institutional and individual investors. Individual
investors can listen to the call at www.fulldisclosure.com,
Thomson/CCBN's individual investor portal, powered by StreetEvents.
Institutional investors can access the call via Thomson's
password-protected event management site, StreetEvents (www.streetevents.com).
A replay of the conference call will be available beginning at 6:30 p.m.
PT on May 8, 2008, for 1 week. Access numbers for this replay are:
1-888-286-8010 (U.S./Canada) and 1-617-801-6888 (international). The
access code for the replay is 35745410.
About VIVUS
VIVUS, Inc., is a pharmaceutical company dedicated to the development
and commercialization of novel therapeutic products. The current
portfolio includes investigational products addressing obesity and
sexual health. The pipeline includes: Qnexa™,
which is in phase 3 for obesity and phase 2 for diabetes; Testosterone
MDTS®, for which a phase 2 study has been
completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD);
and avanafil, for which a phase 2 study has been completed for the
treatment of erectile dysfunction (ED). MUSE®
is approved and currently on the market for the treatment of ED. For
more information on clinical trials and products, please visit the
company's web site at http://www.vivus.com.
|